Progenity Provides Financial Guidance for Full-year 2021
Progenity, Inc. (Nasdaq: PROG) announced its financial guidance for 2021, projecting total revenue growth of up to 30%, with expected earnings between $130 million and $145 million. Core molecular testing revenue is forecasted at $115 million to $125 million, while SARS CoV-2 testing is estimated to generate $15 million to $20 million. The company expects substantial growth in core testing volume, aiming for 290,000 to 310,000 tests. Progenity also emphasizes ongoing cost management and R&D disciplines amidst planned advancements in its product lines.
- Projected total revenue expected to grow by up to 30%, reaching $130 to $145 million.
- Core molecular testing revenue anticipated between $115 million and $125 million.
- SARS CoV-2 testing revenue expected to be $15 to $20 million.
- Core molecular testing volume forecasted at 290,000 to 310,000 tests.
- Commitment to manage SG&A and maintain disciplined R&D expenses.
- Adverse impact to revenue and volume reported in the second half of 2020 due to revenue cycle changes.
Total 2021 revenue expected to grow by up to
Core molecular testing2 volume expected to grow by up to
SAN DIEGO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today provided 2021 full-year financial guidance.
“The year 2020 proved to be a transitional period for Progenity, especially in light of the adverse impact to revenue and volume due to transient revenue cycle changes in the second half of the year. We expect that we will return to strong, sustained revenue and volume growth in 2021 led by expansion of our core product lines and additional testing capacity for SARS CoV-2 test services. We also remain on track to complete the clinical validation of our preeclampsia rule out test, Preecludia™, by mid-year and to prepare for launch in the second half of the year. We’ve also made significant progress with our potentially transformative Innatal 4 technology and continued advances and partnerships negotiations relating to our GI portfolio,” said Harry Stylli, Ph.D., CEO, chairman of the board, and co-founder of Progenity. “In addition, we are committed to actively managing our SG&A costs and will maintain disciplined R&D spend throughout the year.”
Financial Guidance for 2021
| Core molecular testing revenue: | |
| SARS CoV-2 revenue: | |
| Total revenue: | (estimated annual growth of up to |
| SG&A expense: | |
| R&D expense: | |
| Core molecular testing volume2: | 290,000 to 310,000 |
| SARS CoV-2 volume: | 275,000 to 300,000 |
1 Growth of annual 2021 revenue guidance over estimated 2020 revenues ex-accruals (a reconciliation of 2020 revenue ex-accruals to its comparable GAAP figure (revenue) is not available due to the unpredictability of accruals, if any. In addition, the magnitude of any such accruals may be significant, as discussed in our periodic reports previously filed with the SEC.)
2 Volume for Innatal, Preparent, Riscover tests
3 Includes revenues from Avero affiliate
About Progenity
Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies. For more information on how Progenity is helping clinicians and patients prepare for life, please visit www.progenity.com.
Safe Harbor Statement or Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the impact of the COVID-19 pandemic on our business, operations, financial results, and future performance, and the progress of our research and development efforts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release, including revenue, expense and volume guidance for the fiscal year 2021. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, the ongoing COVID-19 pandemic, our ability to develop and commercialize our testing products as well as innovate in the field of precision medicine, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, disputes with third party payors with respect to reimbursement and recoupment, our expectations regarding future revenue, costs and test volumes, our expectations regarding our in network position, anticipated capacity for our tests, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Progenity’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 filed with the SEC and other subsequent documents we file with the SEC.
We expressly disclaim any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact:
Robert Uhl
Managing Director, Westwicke ICR
ir@progenity.com
(619) 228-5886
Media Contact:
Kate Blom-Lowery
CG Life
media@progenity.com
(858) 457-2436
FAQ
What is Progenity's revenue guidance for 2021?
What are the expected revenues from core molecular testing for PROG?
How many SARS CoV-2 tests does Progenity expect to conduct?
What testing volume does Progenity predict for core molecular testing?
What challenges did Progenity face in 2020?
